Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AIMSPRO
- Development stage
- Phase 2
- Lead developer
- Daval International
- Modality
- Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
AIMSPRO is a biologic drug developed by Daval International Limited, consisting of a hyperimmune caprine (goat) serum derivative. The serum is produced by immunizing goats with an HIV-1 lysate, resulting in a product containing polyclonal antibodies and other serum factors. AIMSPRO is believed to exert its therapeutic effects through a tri-partite functionality: targeting the hypothalamic-pituitary-adrenal (HPA) axis, modulating pro-inflammatory cytokines, and lowering the triggering voltage of sodium channels, which may improve nerve conduction in demyelinated axons. It has been primarily investigated in Phase II clinical trials for the treatment of overactive bladder and other symptoms in patients with secondary progressive multiple sclerosis (SPMS), as well as for systemic sclerosis (scleroderma). The drug has also received orphan drug designation from the Australian Therapeutic Goods Administration (TGA) for Krabbe's disease. It is administered as a subcutaneous injection.
- Brand names
- AIMSPRO
- Other names
- Hyperimmune caprine serumAnti-HIV goat serum
02
Targets
NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on AIMSPRO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIMSPRO.